Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New inhaler shows promise for COPD patients in early trial

NCT ID NCT07450482

First seen Apr 13, 2026 · Last updated May 25, 2026 · Updated 7 times

Summary

This study tested a new inhaled drug called JKN2304 in 42 people with moderate to severe COPD. The goal was to see if it is safe and helps improve lung function over 14 days. Participants received either JKN2304, a placebo, or an active comparator drug. The trial has been completed, and results will show how well the drug works and its side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COPD are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Guangzhou First People's Hospital

    Guangzhou, Guangdong, China

  • Huadong Hospital Affiliated to Fudan University

    Shanghai, Shanghai Municipality, China

  • Jiangyin Hospital of Traditional Chinese Medicine

    Jiangyin, Jiangsu, China

  • Liuyang People's Hospital

    Guankou, Hunan, China

  • Shanghai Pudong New Area People's Hospital

    Shanghai, Shanghai Municipality, China

  • The Affiliated Hospital of Yangzhou University

    Yangzhou, Jiangsu, China

  • Weifang Second People's Hospital

    Weifang, Shandong, China

  • Zhangzhou Hospital, Fujian Province

    Zhangzhou, Fujian, China

Conditions

Explore the condition pages connected to this study.